Home Archives 2005

Yearly Archives: 2005

When the backers of California’s stem cell initiative were seeking voter support last year, they not only promised cures for dread diseases, but also licensing revenue for the state. A statement posted on the initiative proponents’ CuresforCalifornia.com Web site says that ‘California will benefit for decades from patents and royalties that result from the research.’ But most biotech IP lawyers say it is foolhardy and wildly optimistic to predict that royalty revenue will come to California in the uncertain area of stem cell-derived therapies.

The pharmaceutical industry was traumatized in 2004 when Merck had to withdraw its $2.5 billion COX-2 inhibitor Vioxx from the market due to potentially lethal side effects. Pharmaceutical companies are already struggling to deal with increasing generic competition and stringent approval standards in an effective manner. Will the aftereffects of a disastrous 2004 hamper industry growth in the years to come?

The Human Genome, Take Two
When a sequenced human genome was announced in 2001, most people missed a crucial part of the news: the genome was a first draft, sketchy and incomplete. This fall, scientists completed a new draft. The more complete version reveals that humans have a few thousand fewer genes than was previously predicted. The new version will also allow researchers to analyze the genome on a larger scale.